SLC52A2
Solute carrier family 52, riboflavin transporter, member 2
Also known as: D15Ertd747e, FLJ11856, GPCR41, GPR172A, hRFT3, PAR1, RFVT2, S52A2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9HAB3
- Gene
- SLC52A2
- Ensembl
- ENSG00000185803
- Chromosome
- 8
- Canonical length
- 445 aa
- Protein class
- Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters
OverviewNCBI Gene
This gene encodes a membrane protein which belongs to the riboflavin transporter family. In humans, riboflavin must be obtained by intestinal absorption because it cannot be synthesized by the body. The water-soluble vitamin riboflavin is processed to the coenzymes flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) which then act as intermediaries in many cellular metabolic reactions. Paralogous members of the riboflavin transporter gene family are located on chromosomes 17 and 20. Unlike other members of this family, this gene has higher expression in brain tissue than small intestine. Alternative splicing of this gene results in multiple transcript variants encoding the same protein. Mutations in this gene have been associated with Brown-Vialetto-Van Laere syndrome 2 - an autosomal recessive progressive neurologic disorder characterized by deafness, bulbar dysfunction, and axial and limb hypotonia. [provided by RefSeq, Jul 2012]
Canonical amino-acid sequenceUniProt
445 residues, UniProt reviewed canonical sequence.
>Q9HAB3|SLC52A2
1 MAAPTPARPV LTHLLVALFG MGSWAAVNGI WVELPVVVKE LPEGWSLPSY VSVLVALGNL
61 GLLVVTLWRR LAPGKDEQVP IRVVQVLGMV GTALLASLWH HVAPVAGQLH SVAFLALAFV
121 LALACCASNV TFLPFLSHLP PRFLRSFFLG QGLSALLPCV LALVQGVGRL ECPPAPINGT
181 PGPPLDFLER FPASTFFWAL TALLVASAAA FQGLLLLLPP PPSVPTGELG SGLQVGAPGA
241 EEEVEESSPL QEPPSQAAGT TPGPDPKAYQ LLSARSACLL GLLAATNALT NGVLPAVQSF
301 SCLPYGRLAY HLAVVLGSAA NPLACFLAMG VLCRSLAGLG GLSLLGVFCG GYLMALAVLS
361 PCPPLVGTSA GVVLVVLSWV LCLGVFSYVK VAASSLLHGG GRPALLAAGV AIQVGSLLGA
421 VAMFPPTSIY HVFHSRKDCA DPCDSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SLC52A2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 11
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 34 nTPM
Expression across tissuesHPA
Tissue
- cerebellum: 34 nTPM
- pancreas: 33 nTPM
- colon: 27 nTPM
- esophagus: 27 nTPM
- spleen: 26 nTPM
- testis: 25 nTPM
Single-cell type
- other brain neurons: 15 nCPM
- brain excitatory neurons: 13 nCPM
- brain inhibitory neurons: 9.2 nCPM
- papillary tip epithelial cells: 9.1 nCPM
- oligodendrocyte progenitor cells: 8 nCPM
- renal collecting duct principal cells: 7.8 nCPM
Immune cell
- naive B-cell: 9.9 nTPM
- eosinophil: 9.2 nTPM
- non-classical monocyte: 7.6 nTPM
- plasmacytoid DC: 7.6 nTPM
- intermediate monocyte: 5.9 nTPM
- T-reg: 5.7 nTPM
Brain region
- cerebellum: 12 nTPM
- hypothalamus: 12 nTPM
- midbrain: 12 nTPM
- medulla oblongata: 12 nTPM
- pons: 11 nTPM
- thalamus: 11 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SLC52A2.
Disease | AllUniProt
Conditions SLC52A2 is implicated in, by any mechanism.
- Brown-Vialetto-Van Laere syndrome 2 (BVVLS2) MIM:614707
Disease | GeneticClinVar
43 pathogenic / likely-pathogenic of 572 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Brown-Vialetto-van Laere syndrome 2
- Inborn genetic diseases
- Mitochondrial disease
- SLC52A2-related disorder
- Brown-Vialetto-van Laere syndrome 1
Disease | ImmuneIEDB
Conditions an epitope on SLC52A2 was assayed in.
- colonic benign neoplasm T cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.98
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.85
- DepMap mean gene effect
- -0.13
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 16% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- riboflavin transmembrane transporter activity
- virus receptor activity
- 4-hydroxybutyrate receptor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SLC52A2 as an antibody target. Whether an autoantibody or antibody against SLC52A2 could matter depends on whether native SLC52A2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SLC52A2 is annotated at the cell surface, where native SLC52A2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label SLC52A2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...